These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 37437437)
21. An elevated preoperative cholesterol-to-lymphocyte ratio predicts unfavourable outcomes in colorectal cancer liver metastasis patients receiving simultaneous resections: a retrospective study. Deng Y; Chen Q; Chen J; Zhang Y; Zhao J; Bi X; Li Z; Zhang Y; Huang Z; Cai J; Zhao H BMC Surg; 2023 May; 23(1):131. PubMed ID: 37194000 [TBL] [Abstract][Full Text] [Related]
22. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization. Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063 [TBL] [Abstract][Full Text] [Related]
23. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. Pak LM; Kemeny NE; Capanu M; Chou JF; Boucher T; Cercek A; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI J Surg Oncol; 2018 Mar; 117(4):634-643. PubMed ID: 29165816 [TBL] [Abstract][Full Text] [Related]
24. Association between imaging response and survival following neoadjuvant chemotherapy in patients with resectable colorectal liver metastases: A cohort study. Behrenbruch C; Prabhakaran S; Udayasiri D D; Michael M; Hollande F; Hayes I; Heriot AG; Knowles B; Thomson BN J Surg Oncol; 2021 Apr; 123(5):1263-1273. PubMed ID: 33524184 [TBL] [Abstract][Full Text] [Related]
25. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases. Correa-Gallego C; Gavane S; Grewal R; Cercek A; Klimstra DS; Gewirtz AN; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N; D'Angelica MI HPB (Oxford); 2015 Jul; 17(7):644-50. PubMed ID: 26010778 [TBL] [Abstract][Full Text] [Related]
26. Multidisciplinary approach to the diagnosis and treatment of patients with potentially resectable colorectal cancer liver metastasis: results of a multicenter study. Han L; Xue J; Wu X; Liang G; Wu Y; Guo F; Gao S; Sun G Ann Palliat Med; 2022 Feb; 11(2):717-729. PubMed ID: 35249349 [TBL] [Abstract][Full Text] [Related]
27. Conversion therapy with the intent to perform radical local treatment may not be suitable for patients with 10 or more liver metastases from colorectal cancer. Lin J; Sun H; Zhang W; Hong Z; Lu Z; Pan Z; Hou Z; Peng J Cancer Med; 2022 Nov; 11(22):4225-4235. PubMed ID: 35466587 [TBL] [Abstract][Full Text] [Related]
28. The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation. Jiang T; Zhang XS; Pan F; Lyu SC; Wang J; Huang MX; He Q; Lang R Medicine (Baltimore); 2021 Jul; 100(26):e26487. PubMed ID: 34190174 [TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of conversion hepatectomy for initially unresectable colorectal liver metastasis. Takamizawa Y; Inoue M; Moritani K; Tsukamoto S; Esaki M; Shimada K; Kanemitsu Y Langenbecks Arch Surg; 2022 Nov; 407(7):2893-2903. PubMed ID: 36068379 [TBL] [Abstract][Full Text] [Related]
30. A novel score system for predicting conversion to no evidence of Disease (C-NED) in initially unresectable colorectal cancer liver metastases. Li W; Zhou J; Zhang T; Tai Y; Xu Y; Bai Y; Jiang Y; Lu Z; Li L; Huang J; Pan Z; Wu X; Peng J; Lin J Am J Cancer Res; 2022; 12(4):1648-1659. PubMed ID: 35530285 [TBL] [Abstract][Full Text] [Related]
31. Optimal surgical sequence for colorectal cancer liver metastases patients receiving colorectal cancer resection with simultaneous liver metastasis resection: A multicentre retrospective propensity score matching study. Chen Q; Zhang R; Xing B; Li C; Xiu D; Chen J; Deng Y; Chen X; Guo R; Chen F; Peng J; Sun T; Wang H; Li M; Zheng Q; Bi X; Zhao J; Zhou J; Li Z; Huang Z; Zhang Y; Zhang Y; Cai J; Zhao H Int J Surg; 2022 Oct; 106():106952. PubMed ID: 36220519 [TBL] [Abstract][Full Text] [Related]
32. Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab. Li S; Yuan L; Yue M; Xu Y; Liu S; Wang F; Liu X; Wang F; Deng J; Sun Q; Liu X; Xue C; Lu T; Zhang W; Zhou J Cancer Imaging; 2023 Mar; 23(1):30. PubMed ID: 36964617 [TBL] [Abstract][Full Text] [Related]
33. Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab. Ye LC; Wei Y; Zhu DX; Chen T; Xu J J Gastroenterol Hepatol; 2015 Apr; 30(4):674-9. PubMed ID: 25387601 [TBL] [Abstract][Full Text] [Related]
34. Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial. Liu Y; Chang W; Zhou B; Wei Y; Tang W; Liang F; Chen Y; Yan Z; Lv M; Ren L; Xu J Br J Surg; 2021 Apr; 108(4):373-379. PubMed ID: 33611431 [TBL] [Abstract][Full Text] [Related]
35. Total tumor volume predicts survival following liver resection in patients with hepatocellular carcinoma. Li MX; Zhao H; Bi XY; Li ZY; Huang Z; Han Y; Zhou JG; Zhao JJ; Zhang YF; Wei WQ; Zhao DB; Cai JQ Tumour Biol; 2016 Jul; 37(7):9301-10. PubMed ID: 26779628 [TBL] [Abstract][Full Text] [Related]
36. The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-type unresectable metachronous colorectal carcinoma with liver metastases. Yu Q; Zhang L; Fan S; Huang L; Wang X; Xindun C J Cancer Res Ther; 2016 Dec; 12(Supplement):C205-C211. PubMed ID: 28230018 [TBL] [Abstract][Full Text] [Related]
37. Hepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases: Outcomes in a newly established program. Walker BS; Billingsley KG; Sutton TL; Kolbeck KJ; Korngold EK; Nabavizadeh N; Dewey EN; Herzig DO; Lopez CD; Mayo SC J Surg Oncol; 2022 Sep; 126(3):513-522. PubMed ID: 35522249 [TBL] [Abstract][Full Text] [Related]
38. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy. Cheng SH; Cheng YJ; Jin ZY; Xue HD Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946 [TBL] [Abstract][Full Text] [Related]
39. [Prognostic factors of patients with unresectable liver metastasis from colorectal cancer after failed conversion chemotherapy]. He H; Shen W; Chen W; Liu H; Gong W; Fu J; Hu X; Cui L Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1261-1267. PubMed ID: 30506537 [TBL] [Abstract][Full Text] [Related]
40. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution. Ammori JB; Kemeny NE; Fong Y; Cercek A; Dematteo RP; Allen PJ; Kingham TP; Gonen M; Paty PB; Jarnagin WR; D'Angelica MI Ann Surg Oncol; 2013 Sep; 20(9):2901-7. PubMed ID: 23771246 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]